Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

BACKGROUND/OBJECTIVES: Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild‐to‐moderate atopic dermatitis (AD). This pooled post hoc analysis of two phase 3 trials (NCT02118766, NCT02118792) assessed improvement and time to improvement in Investigator&#...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichenfield, Lawrence F., Yosipovitch, Gil, Stein Gold, Linda F., Kalabis, Mizuho, Zang, Chuanbo, Vlahos, Bonnie, Sanders, Paul, Myers, Daniela E., Bushmakin, Andrew G., Cappelleri, Joseph C., Olivadoti, Melissa, Paller, Amy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756882/
https://www.ncbi.nlm.nih.gov/pubmed/32981097
http://dx.doi.org/10.1111/pde.14328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756882/
https://www.ncbi.nlm.nih.gov/pubmed/32981097
http://dx.doi.org/10.1111/pde.14328

Ejemplares similares